amifostine anhydrous has been researched along with Anemia, Iron-Deficiency in 1 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Anemia, Iron-Deficiency: Anemia characterized by decreased or absent iron stores, low serum iron concentration, low transferrin saturation, and low hemoglobin concentration or hematocrit value. The erythrocytes are hypochromic and microcytic and the iron binding capacity is increased.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Musch, E | 1 |
| Malek, M | 1 |
| Chrissafidou, A | 1 |
1 other study available for amifostine anhydrous and Anemia, Iron-Deficiency
| Article | Year |
|---|---|
Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Amifostine; Anemia; Anemia, Iron-Deficiency; Drug Therapy, Combination; Ery | 2003 |